Zhonghua Xue Ye Xue Za Zhi. 2025 Mar 14;46(3):209-215. doi: 10.3760/cma.j.cn121090-20250202-00050.
Multiple myeloma is an incurable disease. The bispecific T cell engager, one of the immune therapies targeting tumor cell surface antigens, has shown promising clinical efficacy. However, bispecific T cell engager therapy has a unique anti-myeloma mechanism and adverse effects. To further standardize the clinical application of B cell maturation antigen bispecific T cell engager, the Chinese Myeloma Committee of the Chinese Hematology Association, the Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association and the Society of Hematology of Chinese Geriatrics Association organized experts to formulate the expert consensus by referring to recent domestic and international guidelines, consensus, research progress, and clinical practice, to guide clinical applications better.
多发性骨髓瘤是一种无法治愈的疾病。双特异性T细胞衔接器作为靶向肿瘤细胞表面抗原的免疫疗法之一，已显示出有前景的临床疗效。然而，双特异性T细胞衔接器疗法具有独特的抗骨髓瘤机制和不良反应。为进一步规范B细胞成熟抗原双特异性T细胞衔接器的临床应用，中华医学会血液学分会中国骨髓瘤委员会、中国医师协会血液科医师分会浆细胞疾病学组、中华医学会血液学分会老年血液学组组织专家，参考近期国内外指南、共识、研究进展及临床实践，制定本专家共识，以更好地指导临床应用。
